Paclitaxel Nano-Delivery Systems: A Comprehensive Review. - Wikidata - awgldk - TriplyDB

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

http://www.wikidata.org/entity/Q37250009

about

Albumin-bound paclitaxel in solid tumors: clinical development and future directions Restricted mobility of specific functional groups reduces anti-cancer drug activity in healthy cells Efficient drug delivery of Paclitaxel glycoside: a novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation Abraxane, the Nanoparticle Formulation of Paclitaxel Can Induce Drug Resistance by Up-Regulation of P-gp A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies Organic effects of associating paclitaxel with a lipid-based nanoparticle system on a nonhuman primate, Cebus apella.Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment.Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells.Enhanced antitumor activity of surface-modified iron oxide nanoparticles and an α-tocopherol derivative in a rat model of mammary gland carcinosarcoma.2'-(2-bromohexadecanoyl)-paclitaxel conjugate nanoparticles for the treatment of non-small cell lung cancer in an orthotopic xenograft mouse model.Impact of imaging measurements on response assessment in glioblastoma clinical trials Cationic liposome-nucleic acid complexes for gene delivery and gene silencing.MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.Release kinetics of paclitaxel and cisplatin from two and three layered gold nanoparticles.Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.Effects of Jia-Wei-Xiao-Yao-San on the Peripheral and Lymphatic Pharmacokinetics of Paclitaxel in Rats.From Diagnosis to Treatment: Clinical Applications of Nanotechnology in Thoracic Surgery.Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.Recent advances of cocktail chemotherapy by combination drug delivery systems.Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.Fluorescent Labeling and Biodistribution of Latex Nanoparticles Formed by Surfactant-Free RAFT Emulsion Polymerization.A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours.Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization.Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies.Theranostic nanoemulsions: codelivery of hydrophobic drug and hydrophilic imaging probe for cancer therapy and imaging.The Tumor Microenvironment as a Barrier to Cancer Nanotherapy.NCI investment in nanotechnology: achievements and challenges for the future.Protein based therapeutic delivery agents: Contemporary developments and challenges.Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.Synthesis and Biological Evaluation of New Quinoxaline Derivatives of ICF01012 as Melanoma-Targeting Probes.Nanomedicinal products: a survey on specific toxicity and side effects.Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.Conjugation of Paclitaxel to Hybrid Peptide Carrier and Biological Evaluation in Jurkat and A549 Cancer Cell Lines.Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.Characteristics, Properties and Analytical Methods of Paclitaxel: A Review.

P2860

Q26798674-F28B21FE-00D8-42C9-849D-195861356471 Q27334747-2BFA5DC0-385D-4AC2-8A58-936DC253DD6F Q28543361-79BE1123-1294-4A98-9E03-961AF9DBB07B Q28546603-D5E94686-74B9-4009-AA19-1C6CF31666B4 Q33422212-950AE5EE-5BEA-4B72-B9E8-6C517BA2D8FB Q33719235-F91D9F3F-39F2-42E6-AC27-B8AB2342857B Q33742311-8092537D-F609-45AB-85C0-CCBED2CCDE96 Q33751197-5CADD41A-46EE-4AD3-B0ED-0D93E2FE325D Q33807149-77BECDB8-C27A-4A9D-B31C-36934AC20135 Q34011693-9D20F01C-BEDA-4DB4-A791-8142326A87BD Q34331328-1D7FCADE-C007-430C-A1A1-81526FCFD872 Q34889277-39049BDA-451D-4196-8AE8-84713748297C Q35089472-3931B089-E76E-4C51-93AA-A22FEFFD859B Q35602780-80D6DBE7-A516-4733-992D-21586253E1E7 Q36036923-B447B7EC-9A6B-473E-8895-ADC183D8FAED Q36712831-7437D71F-C39A-4DEE-9B40-E066ABEAAC69 Q36853536-EB358A21-8E4D-4DC9-9CC1-5B3DE68733CE Q36917778-50FBECAE-AE51-4AAE-8CF7-E68053168FC2 Q37031597-147566F4-5CCD-45FB-ADFF-18AD7C52CCEE Q37206908-00A0CE3A-9B05-4FA5-A5AA-2916ECAF4B9E Q37615383-4ECA65AC-0734-4EBA-8975-39103144C18A Q37659699-E93C37D4-7D4F-4306-8133-8213285213CF Q37725419-73FE7BEA-B815-486E-BE16-66734FB2B9B6 Q38726239-2DDED490-0C7E-41CE-B5BC-894B61DE573C Q38733989-CF93D2C5-0148-4BEF-8D06-347742D2ED2D Q38807982-10EC8E77-ED24-4759-B511-BDAFE2FB2C47 Q38856533-A84F6FC4-552C-4370-8EEB-763C672FA98B Q38869805-7BB9E7AC-1CEC-46F3-982A-51028F8497E3 Q38977484-D5E21517-3742-434D-9AF6-EEF0C98FA494 Q38980088-51BFBD86-B2E4-40C8-8E33-8DAFE7917CD0 Q39093463-6E409FE9-99CF-4729-9EAE-D7379A4921D4 Q39273739-A0FE4AA0-121C-4BB3-BF21-D4DDDB51D9B5 Q39508374-E06CB8A1-D6D7-40FE-9EB1-DE107A132DBC Q39782251-AD0D94DE-FFA3-4660-9E7A-387CEFA61200 Q41545896-86C86EBF-A429-4880-A105-0B8C59B80E2C Q42285180-C69CE81B-4D19-47BE-8564-01C07138C2ED Q42364477-62870A86-06B3-4B04-8043-3DF65E004C69 Q44910150-2BE3F6BF-00C8-432C-ABDE-7EAF7329EC9E Q46366459-ACDF2944-953B-45B2-8695-3152921DC4B8 Q47756052-62A058A6-D5C5-4F34-9CFE-38AE3657D845

P2860

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

http://www.wikidata.org/entity/Q37250009

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

@en

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

@nl

type

label

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

@en

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

@nl

prefLabel

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

@en

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

@nl

P1433

Q37250009-163D4982-E913-422A-9536-1EE982C3B7F8

P1476

Q37250009-F19F91F6-A60B-4D11-B329-E65B836EE444

P2093

Q37250009-6BB9BE58-DE81-4839-8C63-191B109DD0E3

Q37250009-8B770153-1112-4338-806B-B1A23E71E084

P2860

Q37250009-0008981B-323D-4702-A801-585CBD139EE9

Q37250009-02010E6E-C907-4DAA-B7CF-3CF1EE2FCBC7

Q37250009-06F85C62-8D3D-4ABC-9E2B-7065873841F2

Q37250009-07BE1021-5E19-4B74-B4E0-A4E43323BE28

Q37250009-089EFE4B-C0AE-498D-B489-711849D5671D

Q37250009-095ADDE3-5465-4E50-9985-E85AE85B84A5

Q37250009-0B265456-6608-4CE2-813F-05E7533E64AC

Q37250009-0C42CBC0-EC01-41EE-A564-705EA6B89DF7

Q37250009-0DE5C9D1-519B-4AAF-A6D1-38ECA990EDA7

Q37250009-0EC2D322-2151-4F30-A23E-B434364FB47A

P304

Q37250009-E00928F7-C5F4-49E9-9573-F4BA6A1C8C6F

P31

Q37250009-4CA79E93-49E1-43FC-80C4-E1AE8B19CF58

P356

Q37250009-CB370FDD-203D-444B-ADDE-27839707BBA8

P433

Q37250009-79FDCEC0-21C9-4302-87D2-D328CCD669EF

P478

Q37250009-5C1B62E1-1152-4AE9-9733-5F8EE600612A

P577

Q37250009-759D53B8-1BE6-4A82-9853-0CC75D5630C1

P5875

Q37250009-87061B1A-EF5B-4474-9679-1E1FD6E39162

P698

Q37250009-58401C27-C557-4DD7-8BD4-969A80867728

P932

Q37250009-02BD0601-6C14-4B1A-909A-02583A231A13

P356

2157-7439.1000164

P1433

Journal of nanomedicine & nanotechnology

P1476

Paclitaxel Nano-Delivery Systems: A Comprehensive Review.

@en

P2093

Ping Ma

http://www.w3.org/2001/XMLSchema#string

Russell J Mumper

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2

Microtubules as a target for anticancer drugs

Amphiphilic beta-cyclodextrins modified on the primary face: synthesis, characterization, and evaluation of their potential as novel excipients in the preparation of nanocapsules.

Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers.

Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs.

Nanoparticles of biodegradable polymers for clinical administration of paclitaxel.

A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS.

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation.

Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy.

Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release.

P304

1000164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4172/2157-7439.1000164

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258104555

http://www.w3.org/2001/XMLSchema#string

P698

24163786

http://www.w3.org/2001/XMLSchema#string

P932

3806207

http://www.w3.org/2001/XMLSchema#string